NZ536111A - Statin therapy for enhancing cognitive maintenance - Google Patents
Statin therapy for enhancing cognitive maintenanceInfo
- Publication number
- NZ536111A NZ536111A NZ536111A NZ53611103A NZ536111A NZ 536111 A NZ536111 A NZ 536111A NZ 536111 A NZ536111 A NZ 536111A NZ 53611103 A NZ53611103 A NZ 53611103A NZ 536111 A NZ536111 A NZ 536111A
- Authority
- NZ
- New Zealand
- Prior art keywords
- statin therapy
- enhancing cognitive
- maintenance
- cognitive maintenance
- statin
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
- 230000001149 cognitive effect Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000012423 maintenance Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960003980 galantamine Drugs 0.000 abstract 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36928502P | 2002-04-02 | 2002-04-02 | |
| PCT/EP2003/003324 WO2003082298A1 (en) | 2002-04-02 | 2003-03-28 | Statin therapy for enhancing cognitive maintenance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ536111A true NZ536111A (en) | 2006-03-31 |
Family
ID=28675573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ536111A NZ536111A (en) | 2002-04-02 | 2003-03-28 | Statin therapy for enhancing cognitive maintenance |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1492539B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005525391A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100986194B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN100528164C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE331523T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003226753B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0308293A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2480275C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1105545T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE60306503T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1492539T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA013069B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2268393T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL164317A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04009535A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20044698L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ536111A (cg-RX-API-DMAC7.html) |
| PL (1) | PL211160B1 (cg-RX-API-DMAC7.html) |
| PT (1) | PT1492539E (cg-RX-API-DMAC7.html) |
| UA (1) | UA79605C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003082298A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
| EP1737539A1 (en) * | 2004-04-14 | 2007-01-03 | Warner-Lambert Company LLC | Therapeutic combination for treatment of alzheimers disease |
| EP1604686A1 (en) * | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| US20160303146A1 (en) * | 2013-12-13 | 2016-10-20 | David A. TABACZYNSKI | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW506836B (en) * | 1996-06-14 | 2002-10-21 | Janssen Pharmaceutica Nv | Fast-dissolving galanthamine hydrobromide tablet |
-
2003
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko not_active Expired - Fee Related
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en not_active Ceased
- 2003-03-28 EP EP03745196A patent/EP1492539B1/en not_active Expired - Lifetime
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
-
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
-
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL211160B1 (pl) | 2012-04-30 |
| CN100528164C (zh) | 2009-08-19 |
| PT1492539E (pt) | 2006-11-30 |
| KR100986194B1 (ko) | 2010-10-07 |
| DE60306503T2 (de) | 2007-06-21 |
| DK1492539T3 (da) | 2006-10-30 |
| PL371551A1 (en) | 2005-06-27 |
| CY1105545T1 (el) | 2010-07-28 |
| IL164317A0 (en) | 2005-12-18 |
| AU2003226753B2 (en) | 2007-06-28 |
| AU2003226753A1 (en) | 2003-10-13 |
| NO20044698L (no) | 2004-10-29 |
| ATE331523T1 (de) | 2006-07-15 |
| EA200401295A1 (ru) | 2005-02-24 |
| DE60306503D1 (de) | 2006-08-10 |
| HK1079688A1 (zh) | 2006-04-13 |
| JP2005525391A (ja) | 2005-08-25 |
| CN1642555A (zh) | 2005-07-20 |
| MXPA04009535A (es) | 2005-01-25 |
| EP1492539B1 (en) | 2006-06-28 |
| UA79605C2 (en) | 2007-07-10 |
| EP1492539A1 (en) | 2005-01-05 |
| ES2268393T3 (es) | 2007-03-16 |
| BR0308293A (pt) | 2004-12-28 |
| KR20040096608A (ko) | 2004-11-16 |
| IL164317A (en) | 2010-04-29 |
| EA013069B1 (ru) | 2010-02-26 |
| CA2480275C (en) | 2011-08-16 |
| WO2003082298A1 (en) | 2003-10-09 |
| CA2480275A1 (en) | 2003-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05008406A (es) | Compuestos de amida tri(ciclo)-sustituida. | |
| MXPA04005790A (es) | Compuestos y usos de los mismos para reducir la actividad de la lipasa sensible a la hormona. | |
| GEP20094759B (en) | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | |
| AU7031500A (en) | Therapeutic quinazoline compounds | |
| WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
| IL195723A (en) | Use of p53 inhibitors for the preparation of medicament | |
| UA84025C2 (en) | Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS | |
| ATE299022T1 (de) | Verwendung von cyclopamine zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
| MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
| MXPA05003253A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos. | |
| PL378369A1 (pl) | Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji | |
| GB9716879D0 (en) | Treatment of attention deficit disorders | |
| PL366800A1 (en) | Tablet comprising cetirizine and pseudoephedrine | |
| GB0020504D0 (en) | Therapeutic method | |
| AP9801202A0 (en) | Atropisomers of 3-heteroaryl-4(3H)-quinazolinones. | |
| CA2370834A1 (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders | |
| GB0215526D0 (en) | Anticancer compounds | |
| MY129643A (en) | Tablet comprising cetirizine and pseudoephedrine | |
| TW200626137A (en) | Preventive or therapeutic agent for sleep disorder | |
| PL367401A1 (en) | Utilization of buprenorphine in urinary incontinence therapy | |
| IL164317A0 (en) | Statin therapy for enhancing cognitive maintenance | |
| IL170519A (en) | Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them | |
| SE0101258D0 (sv) | Treatment of low back pain and whiplash associated disorder | |
| DE60215219D1 (de) | Verwendung von darifenacin zur behandlung des harndrangs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 MAR 2016 BY CPA GLOBAL Effective date: 20130214 |
|
| LAPS | Patent lapsed |